-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, TQMwxykWUnGiAmngY0jhJU43HIJS5OnNtVIUYMyQODOYVTODp6N2dSMHunGeWJKk hTT8LrlqeEtbdD/uMzHqDA== 0000950130-96-001750.txt : 19960517 0000950130-96-001750.hdr.sgml : 19960517 ACCESSION NUMBER: 0000950130-96-001750 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19960425 ITEM INFORMATION: Changes in registrant's certifying accountant ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 19960515 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROGEN CORP CENTRAL INDEX KEY: 0000849043 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 222845714 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-18311 FILM NUMBER: 96565653 BUSINESS ADDRESS: STREET 1: 35 NORTHEAST INDUSTRIAL RD CITY: BRANFORD STATE: CT ZIP: 06405 BUSINESS PHONE: 2034888201 8-K/A 1 FORM 8-K/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________ FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) April 25, 1996 ------------------------------ NEUROGEN CORPORATION - ------------------------------------------------------------------------------ (Exact name of registrant as specified in its charter) DELAWARE 0-18311 22-2845714 - ------------------------------------------------------------------------------ (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 35 Northeast Industrial Road, Branford, Connecticut 06405 - ----------------------------------------------------------------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (203) 488-8201 --------------------------- None ----------------------------------------------------------------------------- (Former name or former address, if changed since last report) Item 4. Changes in Registrant's Certifying Accountant --------------------------------------------- On April 25, 1996, Neurogen Corporation (the "Company"), upon the approval of the Audit Committee of its Board of Directors, elected not to retain KPMG Peat Marwick as its principal independent accountants. On April 26, 1996, the Audit Committee of the Board of Directors appointed Ernst & Young LLP to succeed KPMG Peat Marwick as the principal independent accountants of the Company. The reports of KPMG Peat Marwick on the Company's financial statements for the fiscal years ended December 31, 1994 and December 31, 1995 did not contain an adverse opinion or disclaimer of opinion nor were any of them qualified or modified as to uncertainty, audit scope or accounting principles. Since January 1, 1994, there have been no disagreements between the Company and KPMG Peat Marwick on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure. Item 7. Financial Statements and Exhibits --------------------------------- (c) Exhibits 16.1 Letter from KPMG Peat Marwick dated May 9, 1996 re change in certifying accountant (received by the Company on May 13, 1996). SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROGEN CORPORATION ---------------------------------------- (Registrant) May 14, 1996 /s/ STEPHEN R. DAVIS - ------------------------- ---------------------------------------- DATE Stephen R. Davis Vice President-Finance and Chief Financial Officer Exhibit Index 16.1 Letter from KPMG Peat Marwick dated May 9, 1996 re change in certifying accountant (received by the Company on May 13, 1996). EX-16.1 2 LETTER FROM KPMG PEAT MARWICK Exhibit 16.1 KPMG Peat Marwick LLP 99 High Street Boston, MA 02110 Telephone (617) 988-1000 May 9, 1996 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: We were previously principal accountants for Neurogen Corporation and, under the date of February 12, 1996, we reported on the financial statements of Neurogen Corporation as of and for the years ended December 31, 1995 and 1994. On April 25, 1996, our appointment as principal accountants was terminated. We have read Neurogen Corporation's statements included under Item 4 of its Form 8-K dated April 25, 1996, and we agree with such statements. Very truly yours, KPMG Peat Marwick LLP -----END PRIVACY-ENHANCED MESSAGE-----